Ignite Creation Date:
2024-05-06 @ 12:51 PM
Last Modification Date:
2024-10-26 @ 1:05 PM
Study NCT ID:
NCT03861793
Status:
COMPLETED
Last Update Posted:
2024-03-05
First Post:
2019-02-25
Brief Title:
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 Nemvaleukin Alfa as a Single Agent and in Combination With Anti-PD-1 Antibody Pembrolizumab in Subjects With Select Advanced or Metastatic Solid Tumors ARTISTRY-2
Sponsor:
Mural Oncology Inc
Organization:
Mural Oncology Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-02-26
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03-01
Completion Date Type:
ACTUAL
First Submit Date:
2019-02-25
First Submit QC Date:
March 1 2019
Study First Post Date:
2019-03-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
2024-03-01
Disp First Submit QC Date:
March 1 2024
Disp First Post Date:
2024-03-05
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2024-03-01
Last Update Post Date:
2024-03-05
Last Update Post Date Type:
ACTUAL